The native New Jersey Corporation has been developing a recombinant flu vaccine for the seasonal and pandemic flu virus with a $196 million grant from the Department of Health. This revolutionary vaccine can be produced in large numbers and quickly, in as little as three to four months, as opposed to the traditional vaccine created in eggs or cell cultures.
Right before Christmas this year, VaxInnate announced that they are allowing the biopharmaceutical company CJ CheilJedang Corporation their rights to manufacture and market the vaccine in Southeast Asia, excluding China.
As VaxInnate continues to pursue clinical development and marketing of the vaccine in the United States and Europe, the CJ CheilJedang Corporation will be able to do the same in Asia, expanding their market. The executives at VaxInnate stated that although the deal is a milestone for the company, they strive to make more partnerships to meet global needs.
By Julia Dreifus